S.B. 868 - Controlled Substances Act Amendments

• Excludes apomorphine, thebaine-derived butorphanol, dextrorphan, nalbuphine, nalmefene, naloxegol, naloxone, and naltrexone and their salts from Schedule I narcotic drug classification under opium and opiate provisions.

• Permits individual practitioners to administer, dispense, and prescribe schedule II, III, IV, or V narcotic drugs approved by the FDA specifically for medically-managed withdrawal treatment or maintenance treatment, provided they comply with federal regulations under 21 CFR § 1301.28 and state registration requirements.

• Allows physicians not registered as narcotic treatment program providers to administer narcotic drugs for acute withdrawal symptom relief during a referral process, limited to one day of medication at a time and not to exceed three days total.

• Clarifies that existing provisions do not restrict physicians or hospital staff from administering narcotic drugs as an incidental adjunct to medical or surgical treatment of non-addiction conditions, or for intractable pain management.

• Takes effect July 1, 2050.